Just a moment, the page is loading...
The Supported Studies Programme
Selected Postings:
Clear AllClose

 

Respiratory



Timelines




The following areas are of interest to the Respiratory Supported Studies Committee. These were last updated in September 2019.

[Severe Asthma/COPD/Nasal Polyposis]
• Studies aimed to identify baseline predictors of response to mepolizumab and support its use in patients with eosinophilic conditions
• Studies to provide an understanding how to stratify treatment for a patient who may be eligible for multiple add-on treatments if not controlled at GINA step 4/5
• Evaluating the effectiveness, treatment changes (i.e., OCS use) impact on QoL, and healthcare resource utilization of mepolizumab, in real-world settings, for patients with eosinophilic conditions, including patients with multiple comorbid eosinophilic conditions (i.e., asthma+nasal polyps, asthma+COPD, etc.)
• Research focused on qualitative and patient-centric outcomes in eosinophilic conditions that can improve the measurement of direct or indirect impact of mepolizumab on patients, caregivers, family, employers, and healthcare systems; including the impact and potential benefits of different modes of administration (i.e. at home or clinic administration with autoinjector)
• Studies aimed to improve the identification of patients with multiple comorbid eosinophilic conditions, or to provide a better understanding on the stratification of patients who may be eligible for mepolizumab across multiple eosinophilic conditions
• Research aimed to identify predictive models or biomarkers foreosinophilic conditions in on-going development indications (e.g. predict severe NP progression) – and to identify early response

[Disease mechanism]
• Research focused on understanding the various roles of eosinophils in varying tissue environments, including furthering the understanding of eosinophil subtypes

Although GSK are more likely to support studies aligned to our current areas of interest for supported studies, we are interested in supporting studies that are innovative and contribute to scientific knowledge relating to a product, a medical condition or advancing a technology.



© 2001-2019 GlaxoSmithKline plc. All rights reserved. Registered in England and Wales No. 3888792.
Registered office: 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom.